Home » Authors » Brady Huggett

Articles by Brady Huggett

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Feb. 21, 2002

By Brady Huggett

Vela Raises $25M In Series D To Fund Trials, Add Employees

Feb. 20, 2002

By Brady Huggett

Vela Raises $25M In Series D To Fund Trials, Add Employees

Feb. 20, 2002

By Brady Huggett

Amylin Raises $84M Publicly To Fund AC2993 Phase III Trials

Feb. 13, 2002

By Brady Huggett

Amylin Raises $84M Publicly To Fund AC2993 Phase III Trials

Feb. 13, 2002

By Brady Huggett

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Feb. 12, 2002

By Brady Huggett

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Feb. 12, 2002

By Brady Huggett

Immunex, Genesis Form Pact To Research, Develop Molecules

Feb. 8, 2002

By Brady Huggett

Immunex, Genesis Form Pact To Research, Develop Molecules

Feb. 8, 2002

By Brady Huggett

ZymoGenetics Raises $120M In Year’s First Biotech IPO

Feb. 4, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...